Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
Provided By GlobeNewswire
Last update: Nov 10, 2025
SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2025.
Read more at globenewswire.com23.17
+1.16 (+5.27%)
Find more stocks in the Stock Screener
OLMA Latest News and Analysis
